Evidence map›Paper›PMID 28800492›Full record

SynthesisEuropean journal of cancer (Oxford, England : 1990)2017

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Larysa H M Rydzewska, Sarah Burdett, Claire L Vale, Noel W Clarke, Karim Fizazi, Thian Kheoh, Malcolm D Mason, Branko Miladinovic, Nicholas D James, Mahesh K B Parmar and 6 more

3 registry-linked trialsOpen access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of cancer (Oxford, England : 1990), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 68 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 9 pooled it
17.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00268476 phase2 / phase3active not recruitingnot on this map

STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial

TypeinterventionalSponsorMedical Research CouncilRan2005 to 2030Enrolled11,992ConditionsProstate CancerArmsCelecoxib, Docetaxel, Prednisolone, ADT, Zoledronic Acid
NCT01715285 phase3completednot on this map

A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)

TypeinterventionalSponsorJanssen Research & Development, LLCRan2013 to 2022Enrolled1,209ConditionsProstate NeoplasmsArmsAbiraterone acetate, Prednisone, Androgen deprivation therapy (ADT), Abiraterone acetate Placebo, Prednisone Placebo
NCT01957436 phase3active not recruitingnot on this map

A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer

TypeinterventionalSponsorUNICANCERRan2013 to 2032Enrolled1,173ConditionsMetastatic Prostate CancerArmsabiraterone acetate, radiotherapy, Androgen Deprivation Therapy, Docetaxel
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 9 syntheses or guidelines pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  13. Trial
  14. Trial
  15. Prostate Cancer: Etiology, Diagnosis, and Treatment.Serican journal of medicine · 2026
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

Larysa H M RydzewskaMRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK. Electronic address: larysa.rydzewska@ucl.ac.uk.
Sarah BurdettMRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
Claire L ValeMRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
Noel W ClarkeSalford Royal NHS Foundation Trust, Salford, UK.
Karim FizaziGustave-Roussy, University of Paris Sud, 114 Rue Edouard Vaillant, Villejuif 94800, France.
Thian KheohJanssen Research & Development, San Diego, CA, USA.
Malcolm D MasonCardiff University, School of Medicine, Cardiff, UK.
Branko MiladinovicJanssen Research & Development, San Diego, CA, USA.
Nicholas D JamesInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Queen Elizabeth Hospital, Birmingham, UK.
Mahesh K B ParmarMRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
Melissa R SpearsMRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
Christopher J SweeneyDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Matthew R SydesMRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
NamPhuong TranJanssen Research & Development, Los Angeles, CA, USA.
Jayne F TierneyMRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
STOPCaP Abiraterone Collaborators
MRC Clinical Trials Unit at UCL · GBJanssen (United States) · USCardiff University · GBHarvard University · USQueen Elizabeth Hospital Birmingham · GBSalford Royal NHS Foundation Trust · GBUniversité Paris-Sud · FR

Funding

Medical Research Council MC_UU_12023/25Medical Research Council MC_UU_12023/28
6 · The paper itself

Abstract

backgroundThere is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT.

methodsUsing our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge. Thus, we could determine the earliest opportunity for reliable meta-analysis and take account of unavailable trials in interpreting results. We searched multiple sources for trials comparing AAP plus ADT versus ADT in men with mHSPC. We obtained results for the primary outcome of overall survival (OS), secondary outcomes of clinical/radiological progression-free survival (PFS) and grade III-IV and grade V toxicity direct from trial teams. Hazard ratios (HRs) for the effects of AAP plus ADT on OS and PFS, Peto Odds Ratios (Peto ORs) for the effects on acute toxicity and interaction HRs for the effects on OS by patient subgroups were combined across trials using fixed-effect meta-analysis.

findingsWe identified three eligible trials, one of which was still recruiting (PEACE-1 (NCT01957436)). Results from the two remaining trials (LATITUDE (NCT01715285) and STAMPEDE (NCT00268476)), representing 82% of all men randomised to AAP plus ADT versus ADT (without docetaxel in either arm), showed a highly significant 38% reduction in the risk of death with AAP plus ADT (HR = 0.62, 95% confidence interval [CI] = 0.53-0.71, p = 0.55 × 10

interpretationAdding AAP to ADT is a clinically effective treatment option for men with mHSPC, offering an alternative to docetaxel for men who are starting treatment for the first time. Future research will need to address which of these two agents or whether their combination is most effective, and for whom.

Indexed as

AgedAge FactorsAndrogen AntagonistsAndrostenesAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsChi-Square DistributionClinical Trials as TopicDisease-Free SurvivalHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasms, Hormone-DependentOdds RatioabirateroneAndrogen AntagonistsAndrostenesAntineoplastic Agents, HormonalPrednisolonePrednisoneAbirateroneAndrogen deprivation therapyMeta-analysisMetastasesProstate cancerSystematic review

Identifiers

PMID28800492
PMCPMC5630199
OpenAlexW2743936472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.